Bone Therapeutics has developed two first-in-class products, PREOB® and ALLOB®, which target 3 groups of bone indications in clinical trials and offer the potential for additional product extensions.
In addition, Bone Therapeutics is conducting preclinical research on next generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.